INMB

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Inmune Bio (INMB - Research Report), with a price target of $22.00. The company's shares opened today at $7.43.McCarthy covers the Healthcare sector, focusing on stocks such as Oncolytics Biotech, Daré Bioscience, and Lineage Cell Therapeutics. According to TipRanks, McCarthy has an average return of -38.8% and a 12.86% success rate on recommended stocks. Currently, the analyst consensus on Inmune Bio is a Moderate Buy with an average price target of $22.00.See the top stocks recommended by analysts >>The company has a one-year high of $12.44 and a one-year low of $4.63.
https://www.tipranks.com/news/blurbs/maxim-group-keeps-their-buy-rating-on-inmune-bio-inmb-2?utm_source=advfn.com&utm_medium=referral